Apogee Therapeutics Shows Confidence with Major Director Stock Option Grant

Rhea-AI Filing Summary

Apogee Therapeutics director Mark C. McKenna received a stock option grant on June 17, 2025, according to a Form 4 filing. The derivative securities transaction details include:

• Granted 14,461 stock options to purchase common stock
• Exercise price set at $41.66 per share
• Options will vest fully on the one-year anniversary of the grant date (June 17, 2026)
• Options expire on June 17, 2035
• Vesting is contingent on continued service with the company

The transaction represents a standard director compensation equity grant. The filing was signed by Matthew Batters as attorney-in-fact for McKenna on June 20, 2025. McKenna holds these options under direct ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McKenna Mark C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,461	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,461 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKenna Mark C.

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$41.66	06/17/2025		A		14,461		(1)	06/17/2035	Common Stock	14,461	$0.00	14,461	D

Explanation of Responses:

1. This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for Mark McKenna	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did APGE director Mark McKenna receive in June 2025?

Mark McKenna received 14,461 stock options on June 17, 2025, with an exercise price of $41.66 per share. These options represent the right to purchase APGE common stock and will vest on the one-year anniversary of the grant date (June 17, 2026), subject to McKenna's continued service with the company.

When do Mark McKenna's APGE stock options expire?

The stock options granted to Mark McKenna expire on June 17, 2035, which is 10 years from the grant date of June 17, 2025.

What is the exercise price of APGE director McKenna's stock options?

The exercise price of Mark McKenna's stock options is $41.66 per share of APGE common stock.

What is Mark McKenna's role at APGE according to the Form 4?

According to the Form 4 filing, Mark McKenna serves as a Director of Apogee Therapeutics, Inc. (APGE). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What are the vesting terms for McKenna's APGE stock options?

The stock options will vest in full on the one-year anniversary of the grant date (June 17, 2026), contingent upon McKenna's continued service with Apogee Therapeutics through the vesting date.